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Abstract
Objective—To describe the frequency, attribution, outcome and predictors of seizures in SLE
Methods—The Systemic Lupus International Collaborating Clinics (SLICC) performed a 
prospective inception cohort study. Demographic variables, global SLE disease activity 
(SLEDAI-2K), cumulative organ damage (SLICC/ACR Damage Index (SDI)) and 
neuropsychiatric events were recorded at enrollment and annually. Lupus anticoagulant, 
anticardiolipin, anti-β2 glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor 
antibodies were measured at enrollment. Physician outcomes of seizures were recorded. Patient 
outcomes were derived from the SF-36 mental (MCS) and physical (PCS) component summary 
scores. Statistical analyses included Cox and linear regressions.
Results—The cohort was 89.4% female with a mean follow up of 3.5±2.9 years. 75/1631 (4.6%) 
had ≥1 seizure, the majority around the time of SLE diagnosis. Multivariate analysis indicated a 
higher risk of seizures with African race/ethnicity (HR(CI):1.97 (1.07–3.63); p=0.03) and lower 
education status (1.97 (1.21–3.19); p<0.01). Higher damage scores (without NP variables) were 
associated with an increased risk of subsequent seizures (SDI=1:3.93 (1.46–10.55)); SDI=2 or 
3:1.57 (0.32–7.65); SDI≥4:7.86 (0.89–69.06); p=0.03). There was an association with disease 
activity but not with autoantibodies. Seizures attributed to SLE frequently resolved (59/78(76%)) 
in the absence of anti-seizure drugs. There was no significant impact on the MCS or PCS scores. 
Anti-malarial drugs in absence of immunosuppressive agents were associated with reduced seizure 
risk (0.07(0.01–0.66); p=0.03).
Conclusion—Seizures occurred close to SLE diagnosis, in patients with African race/ethnicity, 
lower educational status and cumulative organ damage. Most seizures resolved without a negative 
impact on health-related quality of life. Anti-malarial drugs were associated with a protective 
effect.
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Nervous system disease in systemic lupus erythematosus (SLE) includes neurological and 
psychiatric events (1–5) of which 19–38% are attributable to lupus.(6) Previous studies 
clustered individual neuropsychiatric (NP) events into groups to study outcomes and impact 
on health-related quality of life (HQol). Although meritorious, assessment of individual NP 
manifestations is preferable but requires a large cohort of patients studied over a prolonged 
period.
Seizures are a manifestation of NPSLE and occur in 6%–51% (1–5) of adult and pediatric 
patients. Most studies have been cross-sectional and have not assessed patients from the time 
of diagnosis of SLE, an important issue in view of reports that seizures are most frequent 
early in the disease course. Here, we report our findings from a large, prospective, 
international, inception cohort of SLE patients. Our objectives were to describe the 
frequency, attribution and outcome of seizure disorders in SLE and to identify clinical and 
laboratory predictors of their occurrence.
Patients and Methods
Research study network
The study was conducted by the Systemic Lupus International Collaborating Clinics 
(SLICC) (7) consisting of 37 investigators in 30 international academic medical centres in 
11 countries. Data were collected per protocol at enrollment and annually thereafter, 
submitted to the coordinating centre in Halifax, Nova Scotia, Canada and entered into a 
centralized Access database. Appropriate procedures ensured data quality, management and 
security. Capital Health Research Ethics Board, Halifax, and each of the participating 
centre’s institutional research ethics review boards approved the study.
Patients
Patients fulfilled the ACR SLE classification criteria SLE,(8) taken as the date of diagnosis, 
and provided written informed consent. Enrollment was permitted up to 15 months 
following the diagnosis. Demographic variables included age, gender, ethnicity, education 
and medication history. Lupus-related variables included the SLE Disease Activity Index 
(SLEDAI-2K) (9) and SLICC/ACR damage index (SDI).(10) Laboratory testing included 
hematology, chemistry and immunology required for SLEDAI-2K and SDI scores.
Neuropsychiatric (NP) events
An enrollment window extended from 6 months prior to the diagnosis of SLE up to the 
enrollment date. NP events were characterized within this window using the ACR case 
definitions for NP syndromes (11), diagnosed by clinical evaluation and supported by 
investigations if clinically warranted as per the guidelines. Patients were reviewed annually 
with a 6-month window around the anticipated assessment date. New NP events since the 
previous study visit were determined at each assessment.
Seizures were classified into either primary generalized seizures with 4 subtypes (tonic 
clonic, atonic, absence and myoclonic) or focal seizures with 2 subtypes (simple and 
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complex).(11) The diagnosis was confirmed by independent description from a reliable 
witness and a normal EEG did not exclude the diagnosis.
Other potential causes (“exclusions”) or contributing factors (“associations”) for each NP 
event (11) were sought. These “non-SLE factors” in part determined the attribution of 
events. For patients with seizures several “exclusions” (vasovagal and cardiac syncope, 
hysteria, hyperventilation, tics, narcolepsy and cataplexy, labyrinthitis, alcohol and drug 
withdrawal, medications quinolones and imipenem, subarachnoid hemorrhage, 
hypoglycemia, panic attacks, conversion disorders, malingering) and “associations” 
(thrombotic thrombocytopenic purpura/microangiopathy, stroke, transient ischemic attack, 
migraine, hypoglycemia (mild), hypoxemia, uremia, intra-cranial tumour and infection) 
were considered.
Recurrent episodes of the same NP event within the enrollment window or follow-up 
assessment period were recorded once. The date of the first episode was taken as the onset of 
the event.
Attribution of NP events
Decision rules were used to determine the attribution of all NP events including seizures. To 
optimize consistency this was performed at the coordinating centre utilizing data provided in 
the case record form by individual SLICC sites. Factors considered in the decision rules 
included: (i) onset of NP event(s) prior to the diagnosis of SLE; (ii) concurrent non-SLE 
factor(s) identified from the ACR glossary for each NP syndrome and (iii); “common” NP 
events which are frequent in normal population controls as described by Ainiala et al.(12) 
These include all headaches, anxiety, mild depression (mood disorders failing to meet 
criteria for “major depressive-like episodes”), mild cognitive impairment (deficits in less 
than 3 of the 8 specified cognitive domains) and polyneuropathy without 
electrophysiological confirmation.
Decision rules of different stringency (models A and B) determined attribution of NP events, 
described in detail elsewhere.(6, 13) NP events that fulfilled criteria for model A (most 
stringent) or for model B (least stringent) were attributed to SLE. By definition, all NP 
events attributed to SLE using model A were included in the group of NP events using 
model B. Events not fulfilling these criteria were attributed to non-SLE causes.
Outcome of seizures
Physician generated 7-point Likert scale compared the change in seizure activity between 
onset and study assessment (1=patient demise, 2=much worse, 3=worse, 4=no change, 
5=improved, 6=much improved, 7=resolved).(14) Patient generated SF-36 questionnaire 
provided mental (MCS) and physical (PCS) component summary scores.(14, 15) These were 
not available to the physicians at the time of assessment.
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Lupus anticoagulant, IgG anticardiolipin, anti-β2 glycoprotein-I, anti-ribosomal P and anti-
NR2 glutamate receptor antibodies were measured at the enrollment visit at the Oklahoma 
Medical Research Foundation, USA using previously described methodology.(16–19)
Statistical analysis
The associations of explanatory variables with the time to the first occurrence of all seizures 
and those attributed to SLE (model B) were examined using Cox proportional hazards 
regression. SF-36 analyses used linear regression and generalized estimating equations with 
a first-order autoregressive correlation structure to allow for correlation between multiple 
SF-36 measurements for the same patient. (See online supplementary text S1).
Results
Patients
1631 patients were recruited between October 1999 and January 2011. The median (range) 
number of patients enrolled in SLICC centres was 36 (8–202). Patients were most frequently 
women (89.4%), with a mean (±SD) age of 35.0±13.4 years and a wide ethnic distribution 
although predominantly Caucasian (Table 1).
At enrollment the mean disease duration was 5.6±4.8 months and 937 (57.5%) patients had 
disease duration <6 months. The prevalence of ACR classification criteria reflected an 
unselected patient population, receiving a typical range of lupus medications. The mean 
SLEDAI-2K and SDI scores indicated moderate global disease activity and minimal 
cumulative organ damage respectively. The number of annual assessments varied from 1 to 
12 with a mean followup of 3.5±2.9 years.
Neuropsychiatric (NP) manifestations
NP (≥1) occurred in 747/1631(45.8%) patients and 336/1631(20.6%) had ≥2 events over the 
study period. The events and their attribution are summarized in Table 2.
There were 1358 NP events, involving all 19 NP syndromes (11). The proportion of NP 
events attributed to SLE varied from 16.9% (model A) to 29.9% (model B) and occurred in 
10.3% (model A) – 17.4% (model B) of patients. Of the 1358 NP events, 1256 (92.5%) 
involved the central nervous system and 102 (7.5%) the peripheral nervous system. The 
classification of events into diffuse and focal was 1071 (78.9%) and 287 (21.1 %), 
respectively.
Seizures
Over the study 75/1631 (4.6%) patients had a seizure. In 59/75 (78.7%), these occurred 
during one observation period and in 16/75 (21.3%) patients, seizures occurred during two 
observation periods. There were a total of 91 seizures (66% generalized; 34% focal) in the 
75 patients and 9 patients had generalized and focal seizures (Table 3).
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Of the 91 seizures 78 (86%) were attributed to SLE. The majority of seizures presented early 
in the disease course with a median (range) interval from the time of SLE diagnosis to onset 
of first seizure of 0.14 (−0.50–7.57) years.
Seizures and other NP events
Of the 91 seizures 36 (39%) occurred in the absence of other NP events within the same 
period of observation; 28 (31%) presented concurrently with other NP events attributed to 
SLE (model B) and 27 (30%) with other NP events not attributed to SLE (model B). 
Seizures attributed to SLE (model B) were more frequent in the absence of other NP events 
compared to those not attributed to SLE (34/78 (44%) vs 2/13 (15%)) although statistical 
significance was not achieved (p=0.07, Fisher’s exact test).
Predictors of seizures
Single-factor analyses revealed that female gender, race/ethnicity, lack of post-secondary 
education, younger age at SLE diagnosis, SDI (total), SDI (without NP) and SDI (without 
seizures) score were individually associated with a higher risk of first occurrence of seizures 
(Table 4).
Concurrent medications were also jointly associated with the risk of first seizure occurrence. 
In particular the current use of corticosteroids and anti-malarial drugs were associated with 
increased and reduced risks, respectively. There was no association with autoantibodies 
individually (Table 4) or after combining lupus anticoagulant, IgG anticardiolipin or anti-β2 
glycoprotein-I into a single antiphospholipid (aPL) panel either for all seizures (HR (CI) 
1.42 (0.82–2.47) or for seizures attributed to SLE (model B) (1.37 (0.78–2.47). Among 1070 
patients with available data for all 3 antibodies, 101 (9.4%) of them had >1 aPL, 279 
(26.1%) had only 1 aPL. Likewise there was no association with individual SLEDAI-2K 
scores. Using the adjusted mean SLEDAI-2K (20) (AMS), 9/25 events which occurred prior 
to the first follow-up assessment, were excluded as computing AMS scores requires a 
minimum of 2 SLEDAI-2K scores. Nevertheless, there was evidence of a relationship with 
seizure occurrence based on these analyses (p=0.07 for AMS (w/o NP variables) and p=0.04 
for AMS (w/o seizures)). Similar results were obtained for seizures attributed to SLE (model 
B) with the exception that the association with SDI scores (without seizures) and current use 
of anti-malarial drugs did not reach statistical significance at the 0.05 level.
Multivariate analysis (Table 5, analysis I) indicated a significant relationship with race/
ethnicity (global test p-value = 0.03) with a higher risk of seizures in African race/ethnicity 
(HR (CI): 1.97 (1.07–3.63)). Higher risk was also associated with lack of post-secondary 
education (1.96 (1.21–3.19); p=0.006) after adjustment for gender, race/ethnicity and age at 
diagnosis, and there was no interaction between race/ethnicity and education (p=0.964). 
Inclusion of SDI scores in the analysis (Table 5, analysis II) reduced the available events for 
analysis from 70 to 20 as SDI scores cannot be computed in patients with <6 months 
disisease duration. Nevertheless, when SDI scores were included, post-secondary education 
remained an important predictor and the association with race/ethnicity was reduced. 
Adjusting for gender, race/ethnicity, age at diagnosis and post-secondary education, patients 
with higher SDI scores (without NP) were associated with an increased risk of subsequent 
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seizures, reaching statistical significance when SDI scores were treated both as a continuous 
variable (1.50 (1.04–2.17); p=0.03) and as a categorical variable (SDI = 1:3.93 (1.46–10.55); 
SDI = 2 or 3:1.57 (0.32–7.65); SDI≥4:7.86 (0.89–69.06); p=0.03). After adjustment for prior 
medications (Table 5, analysis III), this risk was less significant (p=0.07) demonstrating 
confounding between disease severity and medications. An overall association with the four 
specified medication variables was found (global test p-value=0.04). Corticosteroids were 
associated with an increased risk of seizures but with a wide confidence interval. Prior use of 
anti-malarial drugs in the absence of immunosuppressive agents was the most notable 
treatment effect on seizures, conferring a reduced risk (0.07 (0.01–0.66)). A formal test for 
an interaction between anti-malarial drugs and immunosuppressive agents was significant 
(p=0.03).
Without adjusting for SDI scores (see Table 5, analysis IV), the global medication test 
generated a p-value of 0.01 with again a significant interaction (p=0.02). This result derives 
primarily from a comparison of 7 events in 715 observation intervals for patients not taking 
immunosuppresants or anti-malarials versus 2 events in 2210 observation intervals for 
patients taking only anti-malarials. Because of missing values, adjustment for AMS (w/o NP 
variables) alters this finding because 5 events and 225 intervals in the first group and 1 event 
and 655 intervals in the second group are excluded so the interaction, and the global 
medication effect, is not detected. If the missing AMS values are replaced by the current 
SLEDAI-2K values, the significant findings are again seen. Thus, the paucity of data makes 
a definitive statement on the possible confounding of medication and disease activity effects 
difficult. Similar results were obtained for seizures attributed to SLE (model B).
Comparable results were also obtained in a multivariate analysis of medication effects based 
on the inclusion of propensity scores for the use of steroids and anti-malarials alone. Factors 
included in the propensity scores included all those in Table 5, analysis III, as well as 
SLEDAI-2K. More severe disease was linked to steroid use while less severe disease was 
linked to anti-malarials alone. In this analysis, steroid use had an estimated HR of 9.9 with a 
confidence interval of (1.26, 78.57) while anti-malarials alone had an estimated HR of 0.08 
(0.01, 0.70).
Outcome of seizures
Using physician assessment (Figure 1), seizures attributed to SLE were more likely to 
resolve (59/78, (76%)) compared to seizures attributed to non-SLE causes (7/13, (54%)). 
While more patients with seizures attributed to SLE stopped taking anti-seizure drugs at the 
first followup assessment compared to patients with seizures attributed to non-SLE causes 
(19/66=29% vs. 2/12=17%) and similarly by the second followup assessment (16/50=32% 
vs. 1/9=11%), the small number of seizures (especially non-SLE seizures) during the follow-
up period precluded formal statistical testing. Using patient self-report the mean (± SD) 
MCS score in patients with seizures and no other NP events was comparable to patients 
without NP events (45±13.1 vs. 48.5 ± 10.9; p=0.21). A similar outcome was seen in the 
mean (± SD) PCS scores (40.0 ± 10.8 vs. 42.8 ± 11.2; p=0.34).
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Seizures are a manifestation of NPSLE but may follow a different course to idiopathic 
seizures. This has implications for diagnosis and treatment. Previous studies have been 
limited by cross-sectional design, small sample size and short duration of follow-up. We 
studied a large, prospective, international, multi-ethnic, disease inception cohort of adult 
SLE patients. The risk of seizures was higher in patients of African race/ethnicity, lower 
educational status and in patients with organ damage outside of the nervous system. Most 
seizures were attributable to lupus and occurred in close proximity to the diagnosis of SLE. 
Most seizures resolved, did not require long-term anti-seizure medication and were not 
associated with a negative impact on mental or physical health-related quality of life. The 
association with lupus related therapies was complex but anti-malarial drugs were associated 
with a protective effect.
Prevalence estimates of seizures in SLE have varied between 6% (3) and 51%.(5) The 
SLICC cohort is well positioned to determine the frequency of seizures due to the size of the 
cohort, wide global geographic distribution, enrollment of patients close to diagnosis, 
standardized data collection and attribution rules. The cumulative frequency of 4.6% over a 
mean of 3.5 years in our study is comparable to other large studies. For example, 600 
patients in the LUMINA cohort (21) had a frequency of 6.7%, usually early in the disease 
course. Gonzalez-Duarte et al (22) studied 1200 SLE patients of variable disease duration 
and reported long-term outcomes for a subset of the cohort over a mean of 5 years. Seizures 
occurred in 12.5% of patients, 54% of them within one year of SLE diagnosis, and recurred 
in 53%.
Although single-factor analyses identified several variables at enrollment with subsequent 
seizures, African race/ethnicity and lack of post-secondary education remained significant in 
multivariate analysis. The same association with race/ethnicity was reported in the LUMINA 
cohort.(21) Lack of education is a surrogate for socioeconomic status (23) and a predictor of 
functional status (24) and mortality (25) in SLE. In the present study the association with 
education may be due to impaired access or adherence to anti-seizure or lupus related 
therapies. The association with cumulative organ damage has been reported in the LUMINA 
cohort (21) and also in the current study albeit with some confounding with concurrent 
medication use. Overall, these data indicate that lupus patients with seizures have more 
severe disease both within and without the nervous system.
Previous studies have noted that seizures occur in patients with higher global SLE disease 
activity.(21, 26, 27) We did not find an association with higher SLEDAI-2K scores, even in 
patients whose seizures were attributed to SLE. As SLEDAI-2K scores were computed at 
the enrollment and follow-up visits, rather than at the time of seizure occurrence, they do not 
reflect global disease activity at the precise time of the NP event. However, the association 
with AMS and with corticosteroids supports the likelihood that SLE patients with seizures 
likely had more active SLE.
The autoantibodies selected for study reflected those most frequently associated with 
NPSLE. Antiphospholipid antibodies have previously been reported in association with 
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seizures in some (26, 27) but not all studies (22) and no such association was found in the 
current study. This discrepancy may be due to differences in patient selection and study 
design. Alternatively, autoantibody status at the enrollment visit only may be insufficient to 
determine the true risk of these autoantibodies. Rather, an assessment of autoantibodies over 
time may be required to identify a potential clinical-serological linkage.
Of considerable interest is the inverse association between seizures and anti-malarials which 
suggests a possible protective effect, an observation also reported in the LUMINA cohort.
(21) The potential for confounding by indication was addressed in the current study by 
propensity scores and regression modeling in the analysis. Both approaches produced 
similar results in keeping with the findings of Shah et al.(28) Although the precise 
mechanism remains to be determined, our findings further supports the short-term (29) and 
long-term (30–33) benefit associated with anti-malarial use in SLE. This may also explain 
the ability to discontinue anticonvulsant therapy which was more frequent in patients with 
seizures attributed to SLE. Overall, seizure disorders in SLE patients have a favourable 
outcome as indicated by a lower recurrence rate, more frequent discontinuation of anti-
seizure medications, and no detectable impact on patient self-report HRQoL.
There are limitations to the current study. First, a measure of global SLE disease activity was 
not universally available at close proximity to the time of seizure occurrence which limited 
the ability to examine the association with generalized disease activity. Second, the 
association with persistent autoantibodies needs to be examined in subsequent studies. 
Third, the number of patients with seizures attributed to non-SLE causes was relatively 
small which limited the power of some statistical analyses. Finally, although the duration of 
follow-up extended to 12 years, the mean follow-up was 3.5 years which is insufficient to 
capture the life-time experience of SLE patients with seizures. Despite these limitations, the 
size and characteristics of the SLICC NPSLE inception cohort and the standardized 
approach to data collection and analyses has provided information which will help to guide 
management of seizure disorders in SLE patients worldwide. Our findings support the recent 
EULAR recommendations on seizures in SLE patients.(34)
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Kaplan-Meier curves for time to resolution of seizures incorporating attribution models A 
and B over the study period in SLE patients.
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Table 1
Demographic and clinical manifestations of SLE patients at enrollment
N*
Number of Patients 1631 1631
Gender (%)
 Female 1458 (89.4) 1631
 Male 173 (10.6)
Age (years) (mean ± SD) 35.0 ± 13.4 1629
Race/Ethnicity (%):
 Caucasian 780 (47.9) 1629
 Asian 264 (16.2)
 African 264 (16.2)
 Hispanic 254 (15.6)
 Other 67 (4.1)
Single/Married/Other (%) 743 (45.7)/674 (41.4)/210(12.9) 1627
Post secondary education (%) 953 (62.0) (range 32.4–100) 1536
Disease duration (months) (mean ± SD) 5.6 ± 4.8 1631
Number of ACR criteria (mean ± SD) 4.9 ± 1.1 1631
Cumulative ACR manifestations (%) 1631
 Malar rash 589 (36.1)
 Discoid rash 208 (12.8)
 Photosensitivity 585 (35.9)
 Oral/nasopharyngeal ulcers 611 (37.5)
 Serositis 441 (27.0)
 Arthritis 1212 (74.3)
 Renal disorder 441 (27.0)
 Neurological disorder 84 (5.2)
 Hematologic disorder 1008 (61.8)
 Immunologic disorder 1238 (75.9)
 Antinuclear antibody 1546 (94.8)
SLEDAI-2K score (mean ± SD) 5.3 ± 5.4 1616
SLICC/ACR damage index score (mean ± SD) 0.29 ± 0.73 620
Medications (%) 1631
 Corticosteroids 1143 (70.1)
 Anti-malarials 1075 (65.9)
 Immunosuppressants 645 (39.6)
 ASA 232 (14.2)
 Antidepressants 164 (10.1)
 Warfarin 87 (5.3)
 Anticonvulsants 75 (4.6)
 Antipsychotics 11 (0.7)
Autoantibodies [# positive (%)]
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N*
 Lupus anticoagulant 237 (21.2) 1116
 Anticardiolipin 134 (12.5) 1074
 Anti-β2 glycoprotein-I 155 (14.4) 1074
 Anti-ribosomal P 102 (9.6) 1068
 Anti-NR2 glutamate receptor 126 (12.7) 996
*
N is the total number of patients with valid data.
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Table 3
Characteristics of cumulative seizures incorporating attribution models A and B over the study period in SLE 
patients.
Seizures regardless of 
attribution
Seizures due to SLE 
(model A)
Seizures due to SLE 
(Model B)
Seizures due to non-SLE 
causes
Primary generalized 60 39 50 10
 Tonic clonic 57 38 47 10
 Atonic 1 1 1 0
 Absence 2 0 2 0
 Myoclonic 0 0 0 0
Focal seizures 31 20 28 3
 Simple 16 8 15 1
 Complex 15 12 13 2
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